Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10148518 | 0.94 | CYP3A4 (0.39) | CYP3A4CYP2C9 | |
| SCHEMBL881369 | 0.92 | CYP3A4 (0.33) | CYP3A4CYP2C9 | |
| SCHEMBL10149564 | 0.91 | CYP3A4 (0.40) | CYP3A4CYP2C9 | |
| SCHEMBL10149599 | 0.90 | CYP3A4 (0.48) | CYP3A4CYP2C9 | |
| SCHEMBL10148670 | 0.88 | CYP3A4 (0.41) | CYP3A4CYP2C9 | |
| SCHEMBL10148537 | 0.86 | CYP3A4 (0.34) | CYP3A4CYP2C9 | |
| SCHEMBL10171411 | 0.84 | CYP3A4 (0.46) | CYP3A4CYP2C9 | |
| SCHEMBL10149619 | 0.84 | CYP3A4 (0.55) | CYP3A4CYP2C9 | |
| SCHEMBL10171408 | 0.84 | CYP3A4 (0.46) | CYP3A4CYP2C9 | |
| SCHEMBL10148509 | 0.83 | CYP3A4 (0.49) | CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8455451-B2 | 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2013-06-04 | — | — | US | disclosed |
| WO-2012039787-A1 | 2' -FLUORO SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2012-03-29 | — | — | WO | disclosed |
| WO-2012039791-A1 | 2' -FLUORO SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2012-03-29 | — | — | WO | disclosed |